TABLE 1.
BA71 grown in COS-1 cells remains infectious in vivoa
| Virus | Cells used for in vitro amplification | No. of intramuscular doses (dose, PFU) | Clinical outcome (mortality rate, %) | ASFV-specific immune response | % protection after BA71 lethal challenge |
|---|---|---|---|---|---|
| BA71 | PAMs | 1 (100) | Acute ASF (100) | −/+ | NP |
| BA71V | Vero cells | 2 (107) | Asymptomatic (0) | None | 0 |
| BA71-Cos | COS-1 cells | 1 (100) | Acute ASFV (100) | −/+ | NP |
| BA71ΔTKv220i | COS-1 cells | 2 (107) | Asymptomatic (0) | None | 0 |
| BA71ΔTK | COS-1 cells | 2 (107) | Asymptomatic (0) | None | 0 |
a
Groups of 6 animals were inoculated with different quantities and doses of the corresponding recombinant viruses and next challenged with a lethal dose of BA71. ASF clinical signs (including virus detection) and mortality were recorded. −/+, low but detectable anti-ASFV antibodies at time of death; pigs initially inoculated with BA71 and BA71-Cos died of acute ASFV, so rechallenge with BA71 could not be performed (NP).